Extra scrutiny is warranted to identify the underlying causes of chest pain in patients with nonobstructive coronary disease ...

New study shows a longer course of dual antithrombotic therapy may not be necessary for some patients with atrial ...

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026.

Study Links PM2.5 to Over 2,800 Heart Disease Deaths in South Korea Elderly most vulnerable; reducing pollution to 15 μg/m³ ...

Cardiologists advise caution for those recovering from heart issues before flying. Cabin pressure, lower oxygen, and dehydration strain a vulnerable h ...

Longer-term exposure to testosterone therapy was associated with an increased risk for major adverse cardiovascular events among men.

While comedian Kim Soo-yong collapsed due to a sudden loss of consciousness during filming, it was belatedly known that actor ...

Cardiologists warn that indulgent holiday meals can significantly strain the heart, especially for those with existing risk ...

One month of dual antithrombotic therapy followed by direct oral anticoagulation alone may be as safe vs. 1 year of dual ...

A new analysis from the Johns Hopkins Lupus Cohort, published in Annals of the Rheumatic Diseases, provides compelling ...

Bristol Myers Squibb and Johnson & Johnson to discontinue phase 3 Librexia ACS trial of milvexian treat acute coronary syndrome: Princeton, New Jersey Monday, November 17, 2025, 1 ...

Annual Meeting, GE HealthCare will showcase a wave of significant innovations grounded by its legacy and deep, global commitment to advancing precision care. For more than a ...